

2021



DELIC **CORP**

Expanding always. In *all* ways.

You Must Read This Before Continuing

This corporate presentation ("Presentation") is confidential and contains proprietary non-public information regarding Delic Corp ("Delic", the "Company", "we", "us" or "our").


This Presentation is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company. The information contained herein has been prepared for the purpose of providing interested parties with general information to assist them in their evaluation of the Delic. Under no circumstances may the contents of this Presentation be reproduced, in whole or in part, in any form or forwarded or further redistributed to any other person. Any forwarding, distribution or reproduction of this document in whole or in part is unauthorized. By accepting and reviewing this document, you acknowledge and agree (i) to maintain the confidentiality of this document and the information contained herein, and (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care. Delic has not authorized anyone to provide prospective purchasers with additional or different information. In this Presentation all amounts are in Canadian dollars unless stated otherwise.

This Presentation constitutes "forward-looking statements," within the meaning of applicable Canadian and United States securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. These forward-looking statements appear in a number of places throughout this Presentation and can be identified by the use of words, such as "anticipates," or "believes," "budget," "estimates," "expects," or "is expected," "forecasts," "intends," "plans," "scheduled," or variations of such words and phrases or state that certain actions, events or results "may," "might," "will," "would," "could", "should," "continue," or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements. Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, the regulatory regime in which Delic operates, the novel COVID-19, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless otherwise stated, the forward-looking statements contained in this Presentation are made as of the date of this Presentation and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

This Presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed. This Presentation also includes forward-looking statements in respect of potential transactions that are not under contract and no certainty they will complete.

MISSION STATEMENT

Delic Corp is a marketplace for the mainstream to access psychedelic wellness. We create a diverse ecosystem of opportunities by investing in talented entrepreneurs with cutting edge ideas. We lead with 25 years of working knowledge in cannabis, finance, and psychedelic research.



*1

Every
40 seconds
someone in the world
commits suicide.

*2

Ketamine
has shown to
significantly decrease
thoughts of suicide.
In 2019 esketamine
was approved by
the FDA as a
fast-acting
antidepressant.

*3

Traditional palliative
care methods *do not*
successfully treat **end
of life (EOL) anxiety.**

*4

**LSD &
psilocybin** have
shown to reduce EOL
anxiety for terminally
ill patients.

*5

80%
of the terminally ill
patients with psilocybin
sessions experienced
significant reductions in
depression and anxiety.

*6

50%
of Americans will
meet the criteria
for a **mental health
condition** sometime
in their lifetime.

*7

The FDA
granted **psilocybin
therapy** as a
breakthrough therapy
for **depression.**

*8

Approx.
50 million
people in the US are
addicted to some
type of tobacco
product.

*9

Research shows
PSILOCYBIN
is helping people
quit smoking.

Market Potential

~32M^{*9}

People in the US Have Used
Psychedelics at Least Once



~17%^{*10}

Of All American Adults Between
the Ages of 21 and 64

+\$500B^{*11}

Annual US Spend on
Perscription Drugs

\$16B^{*12}

Anxiety Disorder &
Depression Treatment Market

\$71B^{*13}

2016 Spend to Treat
Depressive Disorders

\$238B^{*14}

Annual US Spend on
Mental Health Treatments
& Ancillary Services

\$187.8B^{*15}

2013 US Heathcare Treatment
Spend in the Mental Health &
Substance Abuse Disorders

\$80B^{*16}

Estimated Annual
Spend on Cigarettes

Our team is comprised of leaders, doers and free thinkers. With confidence rooted in the successes of our collective experiences, we are determined to make consious moves that will be a lasting part of our legacy.

OPERATIONS



MATT STANG
CEO/FOUNDER




JACKEE STANG
CCO/FOUNDER



MATHEW LEE
CFO



ZAK GARCIA
CMO




JOHN COLEMAN
VP of BD



DIRECTORS



MARTIN TOBIAS
DIRECTOR



SASHKO DESPOTOVSKI
DIRECTOR



KRAIG FOX
DIRECTOR



PAUL ROSEN
DIRECTOR



DR. MARKUS ROGGEN
DIRECTOR



ADVISORS



SHEP GORDON
ADVISOR



NY TIMES
BESTSELLING AUTHOR



FILM AGENT &
PRODUCER



GREG CROWE
M&A ADVISOR

serendipity



CIO
SERENDIPITY GC

DIRECTOR
14TH ROUND



DR. DAVE RABIN
ADVISOR



CIO & CO-FOUNDER
APOLLO
NEUROSCIENCE



ED & CO-FOUNDER
BOARD OF MEDICINE



BOARD MEMBER
SEMPER FI ODYSSEY



BARBARA BRANAMAN
ADVISOR



CEO & FOUNDER
MEDICINE YOGA



EXECUTIVE VP OF
MARKETING & PRODUCT
CONCENTRIC HEALTH
EXPERIENCE



VP/GM of HOSTING
XO COMMUNICATIONS



GERARD ADAMS
ADVISOR



CO-FOUNDER



PODCAST



KYLE SNOOK
ADVISOR



SENIOR OPERATIONS
EXECUTIVE
STRIVE HEALTH



INFANTRY OFFICER
US ARMY



COO
ACTIFY
NEUROTHERAPIES



GARYN ANGEL
ADVISOR



FOUNDER
MAGICALBUTTER.COM



PRESIDENT
THINKMB - GLOBAL
THINK TANK



PRESIDENT
ANGEL & ASSOCIATES



MICHAEL LOVITCH
ADVISOR



FOUNDING PARTNER
BABY BATHWATER
INSTITUTE



BUSINESS MENTOR:
DIGITAL MARKETING &
BUSINESS GROWTH
CANOPY BOULDER



PARTNER
REAL DOSE NUTRITION



DAVID BELSKY
ADVISOR



CEO & FOUNDER
FLOWHIRE



MOTION
RECRUITMENT
PARTNERS

DELIC ECOSYSTEM

Expanding always. In *all* ways.

Media



Health



Science



Media

Educating and motivating the masses
through a variety of digital platforms.



REALITY SANDWICH DIGITAL MAGAZINE

WEBSITE

- +5000 pieces of free content
- 460k website users in 2020
- 1.4M 2020 website pageviews in 2020
- 551 keywords on 1st page of Google
- 77 keywords in top 3 Google rankings
- Dozen+ images on page one of Google image search

SOCIAL

- 54k followers across all platforms
- +196k monthly reach

EMAIL

- 6,660 subscribers
- 115,600 unique opens in 2020
- 11K unique clicks in 2020

MEET DELIC

VIRTUAL EVENTS

- 2k+ LIVE attendees
- 3k+ Livestream Playbacks

SOCIAL

- +16k followers across all platforms
- +141k monthly reach

EMAIL

- +5k subscribers
- 2k SMS subscribers



DELIC RADIO PSYCHEDELIC WELLNESS



Turn on. Tune in. Drop Out.

PODCAST

- 43+ episodes
- Since Feb 2018
- 100k total streams

The Delic Revolution is Here

DELIC has been featured on the following platforms.



MEET
DELIC



DELIC
CORP



MEET
DELIC



DELIC
CORP



MEET
DELIC



DELIC
CORP

And so are we. 11

Health

Psychedelic treatments have the potential
to help **billions** of people live **happier** lives.



Experienced Management Team

- Over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics
- Exclusively administering IV Ketamine infusion allows us to master the science behind this unique treatment
- Overseeing 4,000 treatments delivered to date

Clinic Economics

- Cost USD\$250,000 to open a clinic
- Average clinic takes 6 months to break even
- Average clinic will do USD \$1m+ of revenue at ~25-30% operating profit
- Plan to open 10 clinics next 18 months

KIC will operate under the DELIC umbrella, under the direction and guidance of Dr. Christopher Ray, Sonny Diaz, Rogelio Monzon, and Ganesh Achary.



DR. CHRISTOPHER RAY



SONNY DIAZ



GANESH ACHARY



ROGELIO MONZON

Science

Advanced extraction and testing facilities
are the backbone of the legal market.



COMPLEX BIOTECH DISCOVERY VENTURES

A licensed cannabis and psilocybin research laboratory.

Founded by award-winning chemists, CBDV focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. CBDV was granted a Section 56 exemption from Health Canada to commence their work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.



DR. MARKUS ROGGEN



PROFESSOR
GLENN SAMMIS

A Strong IP Portfolio

Analytical tools for psychedelic mushroom compounds that advance clinical and end-user testing. Development of psilocybin analogs that could be used in future medical treatments. New projects like “Advanced Analytical Service” and “The Compound Database” will bring scalable revenue streams. The “Extraction Optimization AI” is now starting to be rolled out to the first customers.

Established History of Providing Research and Laboratory Services

CBDV has a history of profitability. Current and past customers are well-established global enterprises who require the cutting-edge cannabis and soon, psilocybin research, which CBDV provides.

Management Expertise

The founding team of CBDV originates from research groups at world-renowned academic institutions. This background instilled an ethos of intellectual curiosity and aspirations of understanding complex concepts through experimentation, research, and analysis.

**Ketamine
Infusion Centers**

Bakersfield, California


Phoenix, Arizona

**Complex Biotech
Discovery Ventures**

Vancouver, Canada

Meet Delic

Los Angeles, CA



CAPITAL STRUCTURE

Basic Issued & Outstanding

55,193,450

Options


4,025,000

Warrants

273,000

Fully Diluted

59,491,450



DELIC CORP

CONTACT

Daniel Southan-Dwyer

(708) 515-4925

invest@deliccorp.com